Compounds > dup 721
Page last updated: 2024-11-11

dup 721

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9882056
CHEMBL ID6462
SCHEMBL ID4402113
MeSH IDM0154443

Synonyms (9)

Synonym
dup-721
CHEMBL6462
SCHEMBL4402113
AKOS030565897
n-[[(5s)-3-(4-acetylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
(s)-n-((3-(4-acetylphenyl)-2-oxooxazolidin-5-yl)methyl)acetamide
MS-23925
EX-A5431
CS-0226367

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent causes for limiting adverse effects in therapy with the sole approved drug of this class, linezolid."( New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
Gordeev, MF; Yuan, ZY, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID274224Antibacterial activity against Staphylococcus aureus UC-76 SA-12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID206547Effective dose required to inhibit Staphylococcus aureus UC9271 in mice subjected to a lethal systemic infection (when administered orally)1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID205577Antibacterial activity against Staphylococcus epidermidis UC30031UC1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID210051Antibacterial activity against Streptococcus pneumoniae UC99121998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID207646Antibacterial activity against Staphylococcus aureus UC92131998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID698976Antimycobacterial activity against Mycobacterium tuberculosis2012European journal of medicinal chemistry, May, Volume: 51Tuberculosis: the drug development pipeline at a glance.
AID68043In vitro minimum inhibitory concentration against Enterococcus faecalis (STCO-19)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group.
AID207263In vitro minimum inhibitory concentration against Staphylococcus aureus (SFCO-1a)1989Journal of medicinal chemistry, Aug, Volume: 32, Issue:8
Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The "B" group.
AID274227Antibacterial activity against Enterococcus faecalis MGH-2 EF1-12006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID207054In vitro for antibacterial activity against Staphylococcus aureus strain SFCO-1a1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group.
AID274226Antibacterial activity against Streptococcus pyogenes C-2032006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID207311Antibacterial activity against Staphylococcus aureus SFCO-1a cell line.1992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives.
AID66921Antibacterial activity against Enterococcus faecalis STCO-191992Journal of medicinal chemistry, Mar-20, Volume: 35, Issue:6
Antibacterials. synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 4. Multiply-substituted aryl derivatives.
AID206546Effective dose required to inhibit Staphylococcus aureus UC9213 in mice subjected to a lethal systemic infection (when administered orally)1998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID67086Antibacterial activity against Enterococcus faecalis UC92171998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID1151705Antibacterial activity against Staphylococcus aureus2014Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile.
AID41245Antibacterial activity against Bacteroides fragilis UC121991998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID274223Antibacterial activity against Escherichia coli by transcription and translation assay2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
AID67419In vitro for antibacterial activity against Enterococcus faecalis strain STCO-191990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group.
AID207645Antibacterial activity against Staphylococcus aureus UC126731998Bioorganic & medicinal chemistry letters, May-19, Volume: 8, Issue:10
Synthesis and antibacterial activity of [6,5,5] and [6,6,5] tricyclic fused oxazolidinones.
AID274225Antibacterial activity against Streptococcus pneumoniae SVI SP-32006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Synthesis and structure-activity studies of novel benzocycloheptanone oxazolidinone antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (14.29)18.7374
1990's3 (42.86)18.2507
2000's1 (14.29)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.90 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (28.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		3.1710carbohydrazideantitubercular agent;
drug allergen
gatifloxacin
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.		3.1710N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		3.7930glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
cephalexin
Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.		1.9710beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative		antibacterial drug
dup 105
4-methylsulfinylphenyloxooxazolidinylmethylacetamide: structure given in first source		3.5120
moxifloxacin
Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.		3.1710aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug
azd2563
posizolid: an antitubercular agent; structure in first source		3.1710
linezolid
[no description available]		4.5640acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
pa 824
pretomanid: nitroimidazopyran derived from 5-nitroimidazoles; a prodrug that requires activation by a bacterial F420-depedent glucose-6-phosphate dehydrogenase (Fgd) and nitroreductase to activate components that then inhibit bacterial mycolic acid and protein synthesis; structure in first source		3.1710
u 100480
U 100480: structure given in first source		3.1710
sq 109
N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine: has antitubercular activity		3.1710
bedaquiline
bedaquiline: a diarylquinoline Antitubercular Agent. bedaquiline : A quinoline-based antimycobacterial drug used (as its fumarate salt) for the treatment of pulmonary multi-drug resistant tuberculosis by inhibition of ATP synthase, an enzyme essential for the replication of the mycobacteria.		3.1710aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound		antitubercular agent;
ATP synthase inhibitor
opc-67683
OPC-67683: an antitubercular agent		3.1710piperidines
gentamicin sulfate
[no description available]		1.9710
tedizolid
DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		3.1910carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
tedizolid phosphate
tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		3.1910carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles		antimicrobial agent;
prodrug;
protein synthesis inhibitor
btz 043
[no description available]		3.1710
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		3.1710cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Bacterial Disease
[description not available]		01.9910
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9910
Koch's Disease
[description not available]		02.9910
Tuberculosis
Any of the infectious diseases of man and other animals caused by species of MYCOBACTERIUM TUBERCULOSIS.		02.9910
Blood Poisoning
[description not available]		03.0110
Bacterial Infections, Gram-Positive
[description not available]		03.0110
Gram-Positive Bacterial Infections
Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.		03.0110
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		03.0110